Welcome!

News Feed Item

Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014

LONDON, Aug. 25, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/2312349/Trigeminal-Neuralgia-Global-Clinical-Trials-Review-H2-2014.html

Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014" provides data on the Trigeminal Neuralgia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Trigeminal Neuralgia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Trigeminal Neuralgia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Trigeminal Neuralgia 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Clinical Trials by G7 Countries: Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials 17
Clinical Trials by Phase 18
In Progress Trials by Phase 19
Clinical Trials by Trial Status 20
Clinical Trials by End Point Status 21
Unaccomplished Trials of Trigeminal Neuralgia 22
Subjects Recruited Over a Period of Time 23
Clinical Trials by Sponsor Type 24
Prominent Sponsors 25
Top Companies Participating in Trigeminal Neuralgia Therapeutics Clinical Trials 26
Prominent Drugs 27
Latest Clinical Trials News on Trigeminal Neuralgia 28
Jun 16, 2014: Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study 28
Clinical Trial Profiles 29
Clinical Trial Overview of Top Companies 29
Merz Pharma GmbH & Co. KgaA 29
Clinical Trial Overview of Merz Pharma GmbH & Co. KgaA 29
Desitin Arzneimittel GmbH 30
Clinical Trial Overview of Desitin Arzneimittel GmbH 30
Convergence Pharmaceuticals Ltd. 31
Clinical Trial Overview of Convergence Pharmaceuticals Ltd. 31
Allodynic Therapeutics, LLC 32
Clinical Trial Overview of Allodynic Therapeutics, LLC 32
Clinical Trial Overview of Top Institutes / Government 33
Stanford University 33
Clinical Trial Overview of Stanford University 33
Thomas Jefferson University 34
Clinical Trial Overview of Thomas Jefferson University 34
University Health Network 35
Clinical Trial Overview of University Health Network 35
National Institute of Dental and Craniofacial Research 36
Clinical Trial Overview of National Institute of Dental and Craniofacial Research 36
Shahid Sadoughi University of Medical Sciences and Health Services 37
Clinical Trial Overview of Shahid Sadoughi University of Medical Sciences and Health Services 37
FDA Office of Orphan Products Development 38
Clinical Trial Overview of FDA Office of Orphan Products Development 38
University of Malaya 39
Clinical Trial Overview of University of Malaya 39
Riken Advanced Science Institute 40
Clinical Trial Overview of Riken Advanced Science Institute 40
University College London 41
Clinical Trial Overview of University College London 41
Capital Medical University 42
Clinical Trial Overview of Capital Medical University 42
Five Key Clinical Profiles 43
Appendix 58
Abbreviations 58
Definitions 58
Research Methodology 59
Secondary Research 59
About GlobalData 60
Contact Us 60
Disclaimer 60
Source 60

List of Tables
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Region, 2014* 7
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Trigeminal Neuralgia Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Trigeminal Neuralgia Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Trigeminal Neuralgia Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Trigeminal Neuralgia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Trigeminal Neuralgia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Trigeminal Neuralgia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 17
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Phase, 2014* 18
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 19
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 20
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, by End Point Status, 2014* 21
Trigeminal Neuralgia Therapeutics, Global, Withdrawn Clinical Trials, 2014* 22
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23
Trigeminal Neuralgia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 24
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Merz Pharma GmbH & Co. KgaA, 2014* 29
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Desitin Arzneimittel GmbH, 2014* 30
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Convergence Pharmaceuticals Ltd., 2014* 31
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Allodynic Therapeutics, LLC, 2014* 32
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 33
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Thomas Jefferson University, 2014* 34
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by University Health Network, 2014* 35
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Dental and Craniofacial Research, 2014* 36
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Shahid Sadoughi University of Medical Sciences and Health Services, 2014* 37
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by FDA Office of Orphan Products Development, 2014* 38
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Malaya, 2014* 39
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Riken Advanced Science Institute, 2014* 40
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by University College London, 2014* 41
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Capital Medical University, 2014* 42

List of Figures
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Trigeminal Neuralgia Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 10
Trigeminal Neuralgia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Trigeminal Neuralgia Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Trigeminal Neuralgia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Trigeminal Neuralgia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 17
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Phase (%), 2014* 18
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 19
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 20
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23
Trigeminal Neuralgia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 24
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
GlobalData Methodology 59


Read the full report:
Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/2312349/Trigeminal-Neuralgia-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

 

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
As hybrid cloud becomes the de-facto standard mode of operation for most enterprises, new challenges arise on how to efficiently and economically share data across environments. In his session at 21st Cloud Expo, Dr. Allon Cohen, VP of Product at Elastifile, will explore new techniques and best practices that help enterprise IT benefit from the advantages of hybrid cloud environments by enabling data availability for both legacy enterprise and cloud-native mission critical applications. By rev...
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busine...
Organizations do not need a Big Data strategy; they need a business strategy that incorporates Big Data. Most organizations lack a road map for using Big Data to optimize key business processes, deliver a differentiated customer experience, or uncover new business opportunities. They do not understand what’s possible with respect to integrating Big Data into the business model.
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, will discuss how they b...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities – ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups. As a result, many firms employ new business models that place enormous impor...
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous a...
SYS-CON Events announced today that Dasher Technologies will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Dasher Technologies, Inc. ® is a premier IT solution provider that delivers expert technical resources along with trusted account executives to architect and deliver complete IT solutions and services to help our clients execute their goals, plans and objectives. Since 1999, we'v...
SYS-CON Events announced today that MIRAI Inc. will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MIRAI Inc. are IT consultants from the public sector whose mission is to solve social issues by technology and innovation and to create a meaningful future for people.
Data scientists must access high-performance computing resources across a wide-area network. To achieve cloud-based HPC visualization, researchers must transfer datasets and visualization results efficiently. HPC clusters now compute GPU-accelerated visualization in the cloud cluster. To efficiently display results remotely, a high-performance, low-latency protocol transfers the display from the cluster to a remote desktop. Further, tools to easily mount remote datasets and efficiently transfer...
In his session at 21st Cloud Expo, Raju Shreewastava, founder of Big Data Trunk, will provide a fun and simple way to introduce Machine Leaning to anyone and everyone. Together we will solve a machine learning problem and find an easy way to be able to do machine learning without even coding. Raju Shreewastava is the founder of Big Data Trunk (www.BigDataTrunk.com), a Big Data Training and consulting firm with offices in the United States. He previously led the data warehouse/business intellige...
SYS-CON Events announced today that TidalScale, a leading provider of systems and services, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale has been involved in shaping the computing landscape. They've designed, developed and deployed some of the most important and successful systems and services in the history of the computing industry - internet, Ethernet, operating s...
SYS-CON Events announced today that TidalScale will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale is the leading provider of Software-Defined Servers that bring flexibility to modern data centers by right-sizing servers on the fly to fit any data set or workload. TidalScale’s award-winning inverse hypervisor technology combines multiple commodity servers (including their ass...
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
Amazon is pursuing new markets and disrupting industries at an incredible pace. Almost every industry seems to be in its crosshairs. Companies and industries that once thought they were safe are now worried about being “Amazoned.”. The new watch word should be “Be afraid. Be very afraid.” In his session 21st Cloud Expo, Chris Kocher, a co-founder of Grey Heron, will address questions such as: What new areas is Amazon disrupting? How are they doing this? Where are they likely to go? What are th...